Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats

Neuropharmacology

Volumn 60, Issue 2-3, 2011, Pages 284-294

  Riddle, Lindsay R ^a   Kumar, Rakesh ^a   Griffin, Suzy A ^a   Grundt, Peter ^b   Newman, Amy Hauck ^b   Luedtke, Robert R ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

D3 dopamine receptors; Dopamine receptors; Dyskinesia; l dopa; Parkinson's Disease

Indexed keywords

APOMORPHINE; BENSERAZIDE; BUSPIRONE; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 (PYRIDIN 2 YL)BENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (PYRIDIN 3 YL)BENZAMIDE; PG 01037; PG 01042; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DYSKINESIA; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MOTOR COORDINATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TREATMENT RESPONSE;

ANIMALS; BENZAMIDES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG PARTIAL AGONISM; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; LEVODOPA; MALE; PIPERAZINES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D3;

EID: 78650804442     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.09.011     Document Type: Article

References (79)

1. V. Asghari, S. Sanyal, S. Buchwaldt, A. Paterson, V. Jovanovic, and H.H.M. Van Tol Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants Journal Neurochemistry 65 1995 1157 1165
2. S. Barik, and R. de Beaurepaire Evidence for a functional role of the dopamine D3 receptors in the cerebellum Brain Research 737 1996 347 350
3. E. Bezard, J.M. Brotchie, and C.E. Gross Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nature Reviews: Neuroscience 2 2001 577 588
4. M.L. Bouthenet, E. Souil, M.P. Martres, P. Sokoloff, B. Giros, and J.C. Schwartz Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA Brain Research 564 1991 203 219
5. J.J. Canales, and S.D. Iversen Psychomotor-activating effects mediated by dopamine D(2) and D(3) receptors in the nucleus accumbens Pharmacology Biochemistry & Behavior 67 2000 161 168
6. M. Carta, T. Carlsson, D. Kirik, and A. Björklund Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833
7. M. Carta, H.S. Lindgren, M. Lundblad, R. Stancampiano, F. Fadda, and M.A. Cenci Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats Journal Neurochemistry 96 2006 1718 1727
8. M.A. Cenci, and M. Lundblad Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson Disease Animal Methods of Movement Disorders 2005 193 208 Chapter B7
9. M.A. Cenci, I.Q. Whishaw, and T. Schallert Animal models of neurological deficits: how relevant is the rat? Nature Reviews: Neuroscience 3 2002 574 579
10. B.R. Chemel, B.L. Roth, B. Armbruster, V.J. Watts, and D.E. Nichols WAY-100635 is a potent dopamine D4 receptor agonist Psychopharmacology (Berlin) 188 2006 244 251
11. J. Chen, G.T. Collins, J. Zhang, C.Y. Yang, B. Levant, J. Woods, and S. Wang Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile Journal Medicinal Chemistry 51 2008 5905 5908
12. C.L. Chio, M.E. Lajiness, and R.H. Huff Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors Molecular Pharmacology 45 1994 51 60
13. W. Chu, Z. Tu, E. McElveen, J. Xu, M. Taylor, R.R. Luedtke, and R.H. Mach Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands Bioorganic & Medicinal Chemistry 13 2005 77 87
14. W.P. Clarke What's for lunch at the conformational cafeteria? Molecular Pharmacology 67 2005 1819 1821
15. I.A. Cliffe A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT(1A) receptor PET radioligands Nuclear Medicine & Biology 27 2000 441 447
16. R.J. Davidson Anxiety and affective style: role of prefrontal cortex and amygdala Biological Psychiatry 51 2002 68 80
17. M. Davis, and C. Shi The amygdala Current Biology 10 2000 R131
18. A. Dekundy, M. Lundblad, W. Danysz, and M.A. Cenci Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behavioral Brain Research 179 2007 76 89
19. M. Delfino, R. Kalisch, M. Czisch, C. Larramendy, J. Ricatti, I.R. Taravini, C. Trenkwalder, M.G. Murer, D.P. Auer, and O.S. Gershanik Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging Neuropsychopharmacology 32 2007 1911 1921
20. W.C. Drevets Neuroimaging abnormalities in the amygdala in mood disorders Annals New York Academy Science 985 2003 420 444
21. B. Dumartin, I. Caillé, F. Gonon, and B. Bloch Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists Journal Neuroscience 18 1998 1650 1661
22. P.B. Everett, and S.E. Senogles D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway Neuroscience Letters 371 2004 34 39
23. G. Fabbrini, J.B. Brotchie, F. Grandas, M. Nomoto, G. Christopher, and C.G. Goetz Levodopa-induced dyskinesias Movement Disorders 22 2007 1379 1389
24. R.T. Fremeau Jr., G.E. Duncan, M.G. Fornaretto, A. Dearry, J.A. Gingrich, G.R. Breese, and M.G. Caron Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission Proceeding National Academy Science USA 88 1991 3772 3776
25. K. Fuxe, L.F. Agnati, K. Jacobsen, J. Hillion, M. Canals, M. Torvinen, B. Tinner-Staines, W. Staines, D. Rosin, A. Terasmaa, P. Popoli, G. Leo, V. Vergoni, C. Lluis, F. Ciruela, R. Franco, and S. Ferré Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease Neurology 9 2003 S19 S23
26. P.A. Garris, and R.M. Wightman Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo Synapse 20 1995 269 279
27. E.A. Gay, J.D. Urban, D.E. Nichols, G.S. Oxford, and R.B. Mailman Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states Molecular Pharmacology 66 2004 97 105
28. P.L. Gendreau, J.M. Petitto, A. Petrova, J. Gariépy, and M.H. Lewis D(3) and D(2) dopamine receptor agonists differentially modulate isolation-induced social-emotional reactivity in mice Behavioral Brain Research 114 2000 107 117
29. A.A. Grace, and J.A. Rosenkranz Regulation of conditioned responses of basolateral amygdala neurons Physiology & Behavior 77 2002 489 493
30. N. Griffon, C. Pilon, F. Sautel, J.C. Schwartz, and P. Sokoloff Two intracellular signaling pathways for the dopamine D3 receptor: opposite and synergistic interactions with cyclic AMP Journal Neurochemistry 6 1997 1 9
31. P. Grundt, E.E. Carlson, J. Cao, C.J. Bennett, E. McElveen, M. Taylor, R.R. Luedtke, and A. Hauck-Newman Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor Journal Medicinal Chemistry 48 2005 839 848
32. P. Grundt, K.M. Prevatt, J. Cao, M. Taylor, C.Z. Floresca, J.-K. Choi, B.G. Jenkins, R.R. Luedtke, and A.H. Newman Heterocyclic analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents Journal Medicinal Chemistry 50 2007 4135 4146
33. N. Hermanowicz Drug therapy for Parkinson's disease Seminars in Neurology 27 2007 97 105
34. D. Hervé, C. Le Moine, J.C. Corvol, L. Belluscio, C. Ledent, A.A. Fienberg, M. Jaber, J.M. Studler, and J.A. Girault Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum Journal Neuroscience 21 2001 4390 4399
35. R.M. Huff Signal transduction pathways modulated by the D2 subfamily of dopamine receptors Cellular Signalling 8 1996 453 459
36. J.N. Joyce Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs Pharmacology & Therapeutics 90 2001 231 259
37. T. Kenakin Efficacy at G-protein-coupled receptors Nature Review Drug Discovery 1 2002 103 110
38. R. Kumar, L.R. Riddle, S.A. Griffin, W. Chu, S. Vangvervong, J. Neissewander, R.H. Mach, and R.R. Luedtke Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa dependent abnormal involuntary movements in rats Neuropharmacology 56 2009 956 969
39. R. Kumar, L.R. Riddle, S.A. Griffin, P. Grundt, A.H. Newman, and R.R. Luedtke Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa dependent abnormal involuntary movements in rats Neuropharmacology 56 2009 944 955
40. E.V. Kuzhikandathil, and G.S. Oxford Dominant-negative mutants identify a role for GIRK channels in D3 dopamine receptor-mediated regulation of spontaneous secretory activity Journal General Physiology 115 2000 697 706
41. E.V. Kuzhikandathil, L. Westrich, S. Bakhos, and J. Pasuit Identification and characterization of novel properties of the human D3 dopamine receptor Molecular & Cellular Neuroscience 26 2004 144 155
42. E.V. Kuzhikandathil, W. Yu, and G.S. Oxford Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines Molecular & Cellular Neuroscience 12 1998 390 402
43. J.E. LeDoux Emotion circuits in the brain Annual Review Neuroscience 23 2000 155 184
44. R.R. Luedtke, and R.H. Mach Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders Current Pharmaceutical Design 9 2003 643 671
45. M. Lundblad, M. Anderson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease European Journal Neuroscience 15 2002 120 132
46. R.G.D. MacKenzie, D. VanLeeuwen, T.A. Pugsley, Y.-H. Shih, S. Demattos, L. Tang, R.D. Todd, and K.L. O'Mally Characterization of the human dopamine D3 receptor expressed in transfected cell lines European Journal Pharmacology 266 1994 79 85
47. S. Maltais, S. C té, G. Drolet, and P. Falardeau Cellular colocalization of dopamine D1 mRNA and D2 receptor in rat brain using a D2 dopamine receptor specific polyclonal antibody Progress in Neuro- Psychopharmacology & Biological Psychiatry 24 2000 1127 1149
48. D. Marcellino, S. Ferré, V. Casadó, A. Cortés, B. Le Foll, C. Mazzola, F. Drago, O. Saur, H. Stark, A. Soriano, C. Barnes, S.R. Goldberg, C. Lluis, K. Fuxe, and R. Franco Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum Journal Biological Chemistry 283 2008 26016 26025
49. J.-C. Martel, N. Leduc, A.-M. Ormire, V. Faucillon, N. Danty, C. Culie, D. Cussac, and A. Newman-Tancredi WAY-100635 has high selectivity for serotonin 5-HT1A versus dopamine D4 receptors European Journal of Pharmacology 574 2007 15 19
50. J.H. Meador-Woodruff, A. Mansour, D.J. Healy, R. Kuehn, Q.Y. Zhou, J.R. Bunzow, H. Akil, O. Civelli, and S.J. Watson Jr. Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain Neuropsychopharmacology 5 1991 231 242
51. 2+ inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions Molecular Brain Research 22 1994 236 244
52. K.A. Neve, J.K. Seamans, and H. Trantham-Davidson Dopamine receptor signaling Journal of Receptors and Signal Transduction Research 24 2004 165 205
53. A.H. Newman, P. Grundt, G. Cyriac, J.R. Deschamps, M. Taylor, R. Kumar, D. Ho, and R.R. Luedtke N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1- yl)-butyl)-heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists Journal Medicinal Chemistry 52 2009 2559 2570
54. A.H. Newman, P. Grundt, and M.A. Nader Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents Journal Medicinal Chemistry 48 2005 3663 3679
55. C.D. Paspalas, and P.S. Goldman-Rakic Microdomains for dopamine volume neurotransmission in primate prefrontal cortex Journal Neuroscience 24 2004 5292 5300
56. V.M. Pickel, J. Chan, C.S. Kearn, and K. Mackie Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens Journal Computational Neurology 495 2006 299 313
57. C. Pilon, D. Lévesque, V. Dimitriadou, N. Griffon, M.P. Martres, J.C. Schwartz, and P. Sokoloff Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line European Journal of Pharmacology 268 1994 129 139
58. S.L. Rauch, L.M. Shin, and C.I. Wright Neuroimaging studies of amygdala function in anxiety disorders Annals New York Academy Science 985 2003 389 410
59. S.W. Robinson, and M.G. Caron Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor Journal Pharmacology Experimental Therapeutics 52 1997 508 514
60. R. Sánchez-Pernaute, B.G. Jenkins, J.K. Choi, Y.C. Iris Chen, and O. Isacson In vivo evidence of D(3) dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias Neurobiology Disease 27 2007 220 227
61. T. Schallert, S.M. Fleming, J.L. Leasure, J.L. Tillerson, and S.T. Bland CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical abalation, parkinsonism and spinal cord injury Neuropharmacology 39 2000 777 787
62. J.C. Schwartz, S. Ridray, R. Bordet, J. Diaz, and P. Sokoloff D1/D3 receptor relationships in brain coexpression, coactivation, and coregulation Advances in Pharmacology 42 1998 408 411
63. S.C. Sealfon, and C.W. Olanow Dopamine receptors: from structure to behavior Trends Neuroscience 23 2000 S34 S40
64. S.E. Senogles The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine Molecular Pharmacology 58 2000 455 462
65. S.E. Senogles D2s dopamine receptor mediates phospholipase D and antiproliferation Molecular & Cellular Endocrinology 209 2003 61 69
66. S.R. Sesack, and D.B. Carr Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia Physiology & Behavior 77 2002 513 517
67. L.H. Shi, D.J. Woodward, F. Luo, K. Anstrom, T. Schallert, and J.Y. Chang High-frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions Brain Research 1013 2004 98 106
68. D.R. Sibley, F.J. Monsma Jr., and Y. Shen Molecular neurobiology of dopaminergic receptors International Review Neurobiology 35 1993 391 415
69. P. Sokoloff, B. Giros, M.P. Martres, M.L. Bouthenet, and J.C. Schwartz Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics Nature 347 1990 146 151
70. M. Suzuki, Y.L. Hurd, P. Sokoloff, J.C. Schwartz, and G. Sedvall D3 dopamine receptor mRNA is widely expressed in the human brain Brain Research 779 1998 58 74
71. J.L. Tillerson, A.D. Cohen, W.M. Caudle, M.J. Zigmond, T. Schallert, and G.W. Miller Forced nonuse in unilateral parkinsonian rats exacerbates injury Journal Neuroscience 22 2002 6790 6799
72. U. Ungerstedt 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome Pharmacological & Therapeutics Part B: General & Systematic Pharmacology 1976 1976 37 40
73. D. Vallone, R. Picetti, and E. Borrelli Structure and function of dopamine receptors Neuroscience Biobehavioral Review 24 2000 125 132
74. S. Vangveravong, E. McElveen, M. Taylor, S.A. Griffin, R.R. Luedtke, and R.H. Mach Identification and pharmacologic characterization of D2 dopamine receptor selective antagonists Bioorganic & Medicinal Chemistry 14 2006 815 825
75. V.J. Watts, and K.A. Neve Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors Molecular Pharmacology 52 1997 181 186
76. D.M. Weiner, A.I. Levey, R.K. Sunahara, H.B. Niznik, B.F. O'Dowd, P. Seeman, and M.R. Brann D1 and D2 dopamine receptor mRNA in rat brain Proceeding National Academy Science USA 88 1991 1859 1863
77. J. Xu, W. Chu, S. Vangveravong, L.A. Jones, J. Lewis, R.R. Luedtke, J.S. Perlmutter, M.A. Mintun, and R.H. Mach [3H]4-(Dimethylamino)-N-[4-(4-(2- methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D3 receptors. I. In vitro characterization Synapse 63 2009 717 728
78. 2 receptor density ratio in the caudate-putamen Synapse 64 2010 449 459
79. I. Yaroslavsky, M. Colletti, X. Jiao, and S. Tejani-Butt Strain differences in the distribution of dopamine (DA-2 and DA-3) receptor sites in rat brain Life Sciences 79 2006 772 776